Valuation: Cell Source, Inc.

Market Cap 24.41M 21.69M 20.24M 18.45M 34.8M 2.35B 35.12M 245M 94.93M 1.2B 91.65M 89.66M 3.85B P/E 2023
-2.65x
P/E 2024 -2.49x
Enterprise Value 34.92M 31.03M 28.96M 26.39M 49.78M 3.36B 50.24M 350M 136M 1.72B 131M 128M 5.51B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
80.32%
Yield 2023 *
-
Yield 2024 -
1 day+2.50%
1 week+95.47%
Current month+100.00%
1 month+58.58%
3 months-11.83%
6 months+2.50%
Current year+64.00%
1 week 0.36
Extreme 0.36
0.82
1 month 0.36
Extreme 0.36
0.82
Current year 0.25
Extreme 0.25
2.25
1 year 0.25
Extreme 0.25
2.25
3 years 0
Extreme 0.0002
2.25
5 years 0
Extreme 0.0002
2.25
10 years 0
Extreme 0
2.55
Manager TitleAgeSince
Chief Executive Officer 66 2014-06-29
Director TitleAgeSince
Chairman 77 2015-05-17
Director/Board Member 82 2021-03-24
Director/Board Member 72 2022-03-09
Date Insider Type Main position Quantity % Market Cap. Importance
8/9/21 Others

Director

800,000 2.4492%
6/30/21 Others

Director

4,860 0.0149%
6/30/21 Others

Chairman

2,976 0.0091%
Change 5-day change 1-year change 3-year change Capi.($)
+2.50%+95.47%+134.29%+22.39% 27.54M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+79.01% 57.39B
+0.89%-0.63%+2.17%+35.99% 47.64B
+0.36%+0.81%+342.39%+748.97% 44.29B
-0.96%-4.50%+24.96%+31.45% 42.5B
-0.20%-0.77%+4.13%+111.69% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.28%+3.28%+31.31%+28.55% 28.53B
+0.05%-1.64%-8.14%-12.10% 24.34B
Average +0.43%-0.53%+61.00%+119.42% 39.06B
Weighted average by Cap. +0.40%-0.84%+57.11%+139.50%

Financials

2023 2024
Net sales - -
Net income -5.32M -4.73M -4.41M -4.02M -7.59M -512M -7.66M -53.4M -20.69M -262M -19.98M -19.54M -839M -4.51M -4.01M -3.74M -3.41M -6.43M -434M -6.49M -45.29M -17.55M -222M -16.94M -16.57M -712M
Net Debt 9.27M 8.24M 7.69M 7.01M 13.22M 892M 13.34M 93.07M 36.06M 456M 34.82M 34.06M 1.46B 10.51M 9.34M 8.71M 7.94M 14.98M 1.01B 15.12M 105M 40.86M 516M 39.45M 38.6M 1.66B
Logo Cell Source, Inc.
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).
Employees
-
Date Price Change Volume
26-10-02 US$0.4000 -14.88% 4,575
26-10-01 US$0.4699 +14.61% 750
26-09-30 US$0.4100 +2.50% 7,310
26-09-29 US$0.4000 -8.53% 11,600
26-09-28 US$0.4373 +4.25% 575
  1. Stock Market
  2. Stocks
  3. CLCS Stock